China Pharma 2014 Outlook: Numerous Hurdles To Clear For The Year Of The Horse
This article was originally published in PharmAsia News
Executive Summary
Essential Drug List tenders, National Drug Reimbursement List revisions and pricing reforms are expected in the year ahead. After China’s compliance probe crisis, can pharma companies recover quickly in the Year of the Horse?